Identification of Novel Fibrosis Modifiers by In Vivo siRNA Silencing
Fibrotic diseases contribute to 45% of deaths in the industrialized world, and therefore a better understanding of the pathophysiological mechanisms underlying tissue fibrosis is sorely needed. We aimed to identify novel modifiers of tissue fibrosis expressed by myofibroblasts and their progenitors...
Main Authors: | Elisabeth H. Vollmann, Lizhi Cao, Aldo Amatucci, Taylor Reynolds, Stefan Hamann, Isin Dalkilic-Liddle, Thomas O. Cameron, Markus Hossbach, Kevin J. Kauffman, Faryal F. Mir, Daniel G. Anderson, Tatiana Novobrantseva, Victor Koteliansky, Tatiana Kisseleva, David Brenner, Jeremy Duffield, Linda C. Burkly |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-06-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253117301646 |
Similar Items
-
Lab-scale siRNA and mRNA LNP manufacturing by various microfluidic mixing techniques – an evaluation of particle properties and efficiency
by: David C. Jürgens, et al.
Published: (2023-07-01) -
Tetrazine-Induced Bioorthogonal Activation of Vitamin E-Modified siRNA for Gene Silencing
by: Xueli Zhang, et al.
Published: (2022-07-01) -
The biogenesis, regulation and functions of transitive siRNA in plants
by: Tan Huijun, et al.
Published: (2024-09-01) -
Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection
by: Aroon Supramaniam, et al.
Published: (2023-06-01) -
Lipid nanoparticle-encapsulated DOCK11-siRNA efficiently reduces hepatitis B virus cccDNA level in infected mice
by: Hikari Okada, et al.
Published: (2024-09-01)